Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

IGH VDJ-RNA-seq of circulating plasma cells at day zero and seven relative to experimental vaccination dosing

ABSTRACT: IGH VDJ-RNA-seq of circulating plasma cells at day zero and seven relative to experimental vaccination dosing

PROVIDER: PRJNA542644 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

IGH VDJ-RNA-seq of circulating plasma cells at day zero and seven relative to experimental vaccination dosing

Project description:IGH VDJ-RNA-sequencing of CD19+IgD-CD27+CD71+CD38+CD20- circulating plasma cells prior to vaccination (day 0) and seven (day 63) days after the third vaccination.

2019-06-01 | GSE131090 | GEO

RNA-seq of circulating Tfh like cells at day zero and seven and 28 relative to experimental vaccination dosing

Project description:Total RNA-sequencing on 150-200 ICOS+CD38+ cTfh cells per person prior to vaccination (day 0), and seven (day 63) and 28 (day 84) days after the third vaccination.

2019-06-01 | GSE131088 | GEO

Igh repertoire analysis in primary pro-B cells from WT and NE1-/- mice (VDJ-seq)

Project description:Analysis of the antibody repertoire composition is now possible using VDJ-seq. We used this recently developed method for unbiased amplification from genomic DNA (gDNA) to directly compare the Igh repertoire of C57Bl/6 (WT) and NE1-/- pro-B cells. We find that a group of contiguous proximal and intermediate VH genes are under-utilized in V->DJ rearrangement in the absence of NE1 revealing a NE1 zone of influence. We report the VH gene usage profile from WT and NE1-/- primary pro-B cells from the VDJ-seq data.

2022-12-22 | GSE203484 | GEO

RNA-seq of circulating Tfh like cells at day zero and seven and 28 relative to experimental vaccination dosing

Project description:RNA-seq of circulating Tfh like cells at day zero and seven and 28 relative to experimental vaccination dosing

| PRJNA542640 | ENA

Rhesus and cynomolgus IGH database of germline VDJ

Project description:Rhesus and cynomolgus IGH genotyping yields comprehensive databases of germline VDJ alleles for in-depth immunological studies

| PRJEB38839 | ENA

RNA-seq of circulating Tfh like cells at day zero and seven relative to seasonal influenza vaccination

Project description:RNA sequencing of 200 ICOS+CD38+CXCR5+PD-1+ cTfh cells immediately prior to, and seven days after influenza vaccination in four individuals

2019-06-01 | E-MTAB-7955 | biostudies-arrayexpress

The superenhancer binding factor Med1 is broadly required for optimally expressing and hypermutating IgH genes as well as for terminating their expression through locus suicide recombination

Project description:Assembly, expression and maturation of the Immunoglobulin heavy (IgH) chain repertoire necessitates long-range 3D-interactions under regulation by the IgH locus Eµ and 3’ regulatory region (3’RR) super-enhancers. In progenitors, Eµ instrumentally supports VDJ recombination notably towards distal VH genes. In mature cells, the 3’RR first boosts the production of membrane-type IgH transcripts. It later attracts Activation-induced cytidine deaminase at three specific locations: VDJ genes undergoing somatic hypermutation (SHM), switch regions undergoing class switch recombination (CSR), and the 3’RR itself during locus suicide recombination (LSR). In plasma cells devoted to abundant Ig secretion, a late long-range effect is to promote high IgH transcription. The Mediator subunit Med1, which binds super-enhancers and has increased activity after phosphorylation by ERK, was previously attributed a role restricted to class-switched cells. We now show its broader impact on IgH expression, both by promoting recombination of distal VH genes in progenitors and by later supporting SHM. Med1-dependence also marks all long-range functions of the 3’RR, including not only intra- but also trans-chromosomal CSR, LSR, optimal BCR expression and the transcriptional boost featured by plasma cells. Altogether, Med1 appears as a major and specific actor of all the long-range tasks effected by the IgH locus super-enhancers beyond transcription.

2022-10-20 | GSE136845 | GEO

Gene Expression during Panobinostat Dosing

Project description:A clinical study evaluating the dosing of an oral HDACi panobinostat in patient infected with HIV-1. Dosing was 20 mg orally, 3 times weekly, every other week for a total of 8 weeks. Gene expression was evaluated in whole PBMCs at baseline (Visit 2), after 3 doses (Visit 4), 4 weeks after dosing (Visit 12) and 6 months after dosing (Visit 13) using the Affymetrix HTA 2.0 gene expression chip

2018-01-30 | GSE109792 | GEO

Analysis of IGH repertoire in MRL/lpr SLE prone mice treated with either control SMO or Long isoform of PRLR SMO

Project description:Purpose: IGH sequencing has revolutionized analysis of structural and functional signatures of B cell clonality. The goals of this study are to compare IGH repertoire of splenic B cells before and after knockdown of long isoform of PRLR. Methods: After amplifying the IGH repertoire of splenic B cells using PCR primers for VHJ558 variable and Cμ constant regions. For next generation sequencing (NGS), a TrueSeq library was prepared by adapter ligation to full-length products and sequenced on the MiSeq Illumina 2x150 bp platform. Results: In this project, Unique nucleotide sequences were identified, their abundances were calculated, and their complementary determining region 3 (CDR3) length, CDR3 spectrum, VDJ usage, and diversity were analyzed using the International Immunogenetics Information System (IMGT) HighV-QUEST software. Controls are included C3,C4,C5,C7,C8 and C9. LFPRLR SMO treated mice samples are: A3,A4,A5,A6,A7 and A8

2023-03-06 | GSE207186 | GEO

Gene Expression during Panobinostat Dosing

Project description:Gene Expression during Panobinostat Dosing

| PRJNA432059 | ENA